WEBULL
News
IMMX
6.42
-4.75%
-0.32
Immix Biopharma Price Target Announced at $14.00/Share by Mizuho
Dow Jones · 1d ago
Mizuho Initiates Coverage On Immix Biopharma with Outperform Rating, Announces Price Target of $14
Benzinga · 1d ago
IMMIX BIOPHARMA INC <IMMX.O>: MIZUHO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $14
Reuters · 1d ago
Immix Biopharma initiated with an Outperform at Mizuho
TipRanks · 1d ago
Weekly Report: what happened at IMMX last week (0202-0206)?
Weekly Report · 1d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 1d ago
Immix Biopharma Inc. unveils new presentation on relapsed/refractory AL amyloidosis treatment challenges
Reuters · 5d ago
Weekly Report: what happened at IMMX last week (0126-0130)?
Weekly Report · 02/02 10:34
BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, Sherwin-Williams, Caterpillar
Reuters · 01/28 18:37
BUZZ-U.S. STOCKS ON THE MOVE-Amneal Pharma, Ardelyx, Snap
Reuters · 01/28 15:48
BUZZ-Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy
Reuters · 01/28 14:01
Immix Biopharma Granted Breakthrough Therapy Designation From FDA To NXC-201 To Treat Relapsed/Refractory AL Amyloidosis
Benzinga · 01/28 13:48
FDA Grants Breakthrough Therapy Designation to Immix Biopharma's NXC-201 for AL Amyloidosis
Reuters · 01/28 13:45
IMMIX BIOPHARMA INC: FINAL DATA EXPECTED THIS YEAR FOLLOWED BY PLANNED BLA SUBMISSION
Reuters · 01/28 13:45
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
Barchart · 01/28 07:45
Tuesday After-Hours Session Sees Broad Gains Across Healthcare And Biotech
NASDAQ · 01/28 03:58
Weekly Report: what happened at IMMX last week (0119-0123)?
Weekly Report · 01/26 10:34
Weekly Report: what happened at IMMX last week (0112-0116)?
Weekly Report · 01/19 10:41
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities
Benzinga · 01/12 15:48
Weekly Report: what happened at IMMX last week (0105-0109)?
Weekly Report · 01/12 10:40
More
Webull provides a variety of real-time IMMX stock news. You can receive the latest news about Immix Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.